Robert E. Beardmore

TL;DR: Finding the most potent combinations of antibiotics in the lab can be a challenge if antibiotic interactions are not robust to evolutionary adaptation.

TL;DR: The bistable expression of virulence genes in Salmonella allows a clonal population to hedge its bets: one subpopulation suffers a growth cost, but is tolerant to antibiotics.

TL;DR: Collateral sensitivity can result from resistance mutations in regulatory genes such as nalC or mexZ, which mediate aminoglycoside sensitivity in β-lactam-adapted populations, or the two-component regulatory system gene pmrB, which enhances penicillin sensitivity in gentamicin-resistant populations, which in turn determine their potential in antibiotic therapy.

TL;DR: The possibility of a new general mechanism of stable diversity maintenance, one that stems from metabolic and physiological trade-offs, is demonstrated and predicted, which predicts the enigmatic richness of metabolic strategies in clonal bacteria and questions the safety of lethal mutagenesis as an antimicrobial treatment.

TL;DR: The aim is to compare a combination treatment consisting of two synergistic antibiotics to so-called sequential treatments in which the choice of antibiotic to administer can change with each round of treatment, and to optimise the simultaneous use of two antibiotics.